Dade Behring Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dade Behring Inc.
Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.
The firm's health-care division bought private next-generation sequencing firm NEO New Oncology for an undisclosed amount.
Although prostate problems have plagued men for many years, the growing elderly population is now driving an unprecedented increase in caseloads and a corresponding need for improved treatments. One of the primary concerns is the rise in prostate cancer diagnoses. With more than two million American men currently living with prostate cancer and more than 200,000 new cases diagnosed each year, the market for diagnostic and therapeutic products to address this disease is substantial; more than $2 billion in the US in 2007.
In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for July-September 2007. Our data are derived from Windhover's Strategic Transactions Database.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Therapeutic Drug Monitoring
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.